2011 american college of rheumatology recommendations …the american college of rheumatology is an...

2011 American College of RheumatologyRecommendations for the Treatment of JuvenileIdiopathic Arthritis: Initiation and SafetyMonitoring of Therapeutic Agents for theTreatment of Arthritis and Systemic FeaturesTIMOTHY BEUKELMAN,1 NIVEDITA M. PATKAR,1 KENNETH G. SAAG,1 SUE TOLLESON-RINEHART,2

RANDY Q. CRON,1 ESI MORGAN DEWITT,3 NORMAN T. ILOWITE,4 YUKIKO KIMURA,5

RONALD M. LAXER,6 DANIEL J. LOVELL,3 ALBERTO MARTINI,7 C. EGLA RABINOVICH,8 AND

NICOLINO RUPERTO7

Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) areintended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient.The ACR considers adherence to these guidelines and recommendations to be voluntary, with the ultimate determi-nation regarding their application to be made by the physician in light of each patient’s individual circumstances.Guidelines and recommendations are intended to promote beneficial or desirable outcomes but cannot guaranteeany specific outcome. Guidelines and recommendations developed or endorsed by the ACR are subject to periodicrevision as warranted by the evolution of medical knowledge, technology, and practice.

These recommendations have been reviewed and en-dorsed by the Arthritis Foundation.

INTRODUCTION

Juvenile idiopathic arthritis (JIA) is defined by the Inter-national League of Associations for Rheumatology (ILAR)as arthritis of unknown etiology that begins before thesixteenth birthday and persists for at least 6 weeks with

other known conditions excluded (1). JIA is one of themore common chronic diseases of childhood, with a prev-alence of approximately 1 per 1,000 (2,3). JIA often persistsinto adulthood and can result in significant long-term mor-bidity, including physical disability (4–9). Recent major

Supported by a grant from the American College of Rheu-matology and supported in part by the University of Ala-bama at Birmingham Deep South Musculoskeletal Centerfor Education and Research on Therapeutics (Agency forHealthcare Research and Quality grant U18-HS016956). Dr.Beukelman’s work was supported by the NIH (grant 5KL2-RR025776-03) via the University of Alabama at BirminghamCenter for Clinical and Translational Science.

1Timothy Beukelman, MD, MSCE, Nivedita M. Patkar,MD, MSPH, Kenneth G. Saag, MD, MSc, Randy Q. Cron, MD,PhD: University of Alabama at Birmingham; 2Sue Tolleson-Rinehart, PhD: University of North Carolina at Chapel Hill;3Esi Morgan DeWitt, MD, MSCE, Daniel J. Lovell, MD, MPH:Cincinnati Children’s Hospital Medical Center, Cincinnati,Ohio; 4Norman T. Ilowite, MD: Children’s Hospital at Mon-tefiore, Bronx, New York; 5Yukiko Kimura, MD: SanzariChildren’s Hospital at Hackensack University Medical Cen-ter, Hackensack, New Jersey; 6Ronald M. Laxer, MDCM,FRCPC: University of Toronto and Hospital for Sick Chil-dren, Toronto, Ontario, Canada; 7Alberto Martini, MD,

Nicolino Ruperto, MD, MPH: IRCCS Istituto G. Gaslini andUniversity of Genoa, Pediatria II, Reumatologia, Genoa,Italy; 8C. Egla Rabinovich, MD, MPH: Duke University, Dur-ham, North Carolina.

Dr. Saag has received consultant fees, speaking fees,and/or honoraria (less than $10,000 each) from Merck, Lilly,Novartis, P&G, Aventis, Genentech, Takeda, AstraZeneca,and Horizon. Dr. Ilowite has received consultant fees,speaking fees, and/or honoraria (less than $10,000) fromGenentech. Dr. Kimura has served on the advisory board forGenentech and received a fee (less than $10,000). Dr. Laxeris the Chair of the advisory board for Novartis and receivesa fee (less than $10,000). Dr. Martini has received consultantfees, speaking fees, and/or honoraria (less than $10,000)from Bristol-Myers Squibb. Dr. Ruperto has received con-sultant fees, speaking fees, and/or honoraria (less than$10,000 each) from Bristol-Myers Squibb, Roche, and No-vartis.

Members of the Core Expert Panel: Timothy Beukelman,MD, MSCE, Randy Q. Cron, MD, PhD, Esi Morgan DeWitt,MD, MSCE, Norman T. Ilowite, MD, Yukiko Kimura, MD,Ronald M. Laxer, MDCM, FRCPC, Daniel J. Lovell, MD,MPH, Alberto Martini, MD, C. Egla Rabinovich, MD, MPH,Nicolino Ruperto, MD, MPH.

Arthritis Care & ResearchVol. 63, No. 4, April 2011, pp 465–482DOI 10.1002/acr.20460© 2011, American College of Rheumatology

SPECIAL ARTICLE

465

advances in treatment have greatly improved short- andmedium-term outcomes for children with JIA (10–17), yetno validated guidelines offer recommendations for thetreatment of JIA.

To develop recommendations for the safest and mosteffective treatment of JIA on behalf of the American Col-lege of Rheumatology (ACR), we applied the establishedResearch and Development/University of California at LosAngeles (RAND/UCLA) Appropriateness Method (18) toderive recommendations that are as evidence based aspossible. Similar methods were used recently in the de-velopment of the ACR recommendations for the use ofdisease-modifying antirheumatic drugs (DMARDs) forrheumatoid arthritis (19) and the management of glucocor-ticoid-induced osteoporosis (20). We sought to give ourrecommendations additional strength by following theprinciples of the Appraisal of Guidelines for Research andEvaluation instrument (21), a framework designed specif-ically to assess the quality of clinical practice guidelines,including the methods used for their development and thecontent of the final recommendations.

Our effort focused on the initiation and safety monitor-ing of therapeutic agents in the treatment of JIA, includingnonsteroidal antiinflammatory drugs (NSAIDs), intraartic-ular glucocorticoid injections, nonbiologic DMARDs, bio-logic DMARDs, and systemic glucocorticoids for the treat-ment of the systemic features of systemic arthritis. The

indications for systemic glucocorticoids for the treatmentof synovitis were not considered, owing to a lack of pub-lished evidence. We did not consider all ILAR categoriesof JIA individually and instead grouped children with JIAinto distinct “treatment groups” (see Materials and Meth-ods). We did not consider the economic costs of JIA or itstreatment for two reasons: first, too few economic analysesof JIA exist to permit conclusions; second, the RAND/UCLA Appropriateness Method specifically does not con-sider cost implications (18). These recommendations weredeveloped with international input and are intended toinform and benefit health care providers caring for chil-dren with JIA throughout the world. Many recommenda-tions fall outside the present bounds of regulatory agency–approved labeling, but reflect common and widelyaccepted practices in the field.

The products of this project are termed “recommenda-tions” rather than guidelines in order to reflect their non-prescriptive nature. They are meant to function as a refer-ence and do not serve as a substitute for individualizedpatient assessment and clinical decision making, espe-cially when conducted by specialist clinicians familiarwith the treatment of JIA. Importantly, these recommen-dations are not intended to limit health care coverage forchildren with JIA.

MATERIALS AND METHODS

RAND/UCLA Appropriateness Method overview. TheRAND/UCLA Appropriateness Method was originally de-veloped to help determine when the benefits of a medicalintervention outweigh the risks (18) with the understand-ing that the published literature often does not provideevidence at the level of detail required to guide decisionsin everyday clinical practice. This method relies upon theefforts of two distinct groups of participants: the CoreExpert Panel (CEP) and the Task Force Panel (TFP). OurCEP was composed of experienced pediatric rheumatolo-gists from the US, Canada, and Europe who are among theworld’s leaders in the investigation of the treatment of JIA.The TFP contained internationally recognized pediatricrheumatology clinicians and researchers from the US, Can-ada, and Europe; an advanced practice pediatric rheuma-tology nurse; a general pediatrician with expertise in evi-dence-based medicine; and a patient representative, i.e., aparent of a child with JIA who has broad experience in JIAand family treatment preferences.

The initial step was a systematic review of the literature,which was then used by the CEP to prepare a summaryreport of the latest scientific evidence. Concurrently, theCEP prepared a comprehensive list of clinical scenarios (orpotential indications) for each medical intervention of in-terest to be addressed by the recommendations. The sce-narios categorized hypothetical patients using all possiblecombinations of key clinical parameters, such as diseaseactivity and prognostic features, relevant to the decisionprocess. The evidence report and the clinical scenarioswere presented to the TFP for their review.

Evaluation of the scenarios by the TFP led directly to therecommendations for each medical intervention. In thefirst round of voting, the TFP anonymously and indepen-

Members of the Task Force Panel: Suzanne L. Bowyer, MD(Indiana University School of Medicine, Indianapolis),Pavla Dolezalova, MD, PhD (Charles University, Prague,Czech Republic), Ciaran M. Duffy, MBBCh, MSc (McGillUniversity, Montreal, Quebec, Canada), James P. Guevara,MD, MPH (Children’s Hospital of Philadelphia, Philadel-phia, PA), Anne Murphy, PhD (University of California, SanDiego), Murray H. Passo, MD (Medical University of SouthCarolina, Charleston), Marilynn Punaro, MD (University ofTexas Southwestern, Dallas), Rayfel Schneider, MBBCh,FRCPC (University of Toronto and Hospital for Sick Chil-dren, Toronto, Ontario, Canada), David D. Sherry, MD (Chil-dren’s Hospital of Philadelphia, Philadelphia, PA), Earl D.Silverman, MD, FRCPC (University of Toronto and Hospitalfor Sick Children, Toronto, Ontario, Canada), Janalee Tay-lor, RN, MSN, CPNP (Cincinnati Children’s Hospital Medi-cal Center, Cincinnati, OH), Carol A. Wallace, MD (SeattleChildren’s Hospital Medical Center, Seattle, WA).

Members of the University of Alabama at BirminghamWorking Group: Sheree Carter, RN, MSN, Jeffrey R. Curtis,MD, MPH, Archana Jain, MD, Amy Mudano, MPH, Pongth-orn Narongroeknawin, MD.

Members of the University of North Carolina at ChapelHill Working Group: Rachel Fesperman, MD, MPH, BethanyKoestner, MSLS, Lynne Morris, MLS, Karen Rusak, MD,MPH.

American College of Rheumatology Board of DirectorsLiaison: Raphael Hirsch, MD (University of Pittsburgh, Pitts-burgh, PA).

The American College of Rheumatology is an independentprofessional, medical, and scientific society which does notguarantee, warrant, or endorse any commercial product orservice.

Address correspondence to Timothy Beukelman, MD,MSCE, Pediatric Rheumatology, University of Alabama atBirmingham, 1600 7th Avenue South CPP 210, Birmingham,AL 35233-1711. E-mail: [email protected].

Submitted for publication June 29, 2010; accepted in re-vised form December 6, 2010.

466 Beukelman et al

dently rated the appropriateness of the medical interven-tions in the clinical scenarios based on the scientific evi-dence and their best clinical judgment. Differences inopinion from the first round of voting were discussed at aface-to-face meeting, followed by a second rating of theclinical scenarios. The final ratings were compiled andassessed by the CEP and no significant discrepancies wereidentified. Finally, the ratings were used by the CEP tocreate recommendations from the clinical scenarios.

Scope of recommendations. These recommendationscover the indications and safety monitoring for the use ofNSAIDs, intraarticular glucocorticoid injections, nonbio-logic DMARDs, biologic DMARDs, and systemic glucocor-ticoids for the treatment of the systemic features of sys-temic arthritis. In contrast to prior ACR recommendations,the scope of this project was not explicitly established bythe ACR, but rather by the CEP members. An exhaustivelist of broad potential topics for inclusion was constructedby the principal investigator (TB) and reviewed and re-vised by 3 other authors (RQC, EMD, KGS). The resultantlist of 23 potential topics for consideration was distributedto all CEP members. Using a modified Delphi process viaelectronic mail, the list of topics was prioritized and grad-ually shortened until it was deemed feasible in the timeallotted to the project. As a result, several relevant topicswere necessarily omitted. Medication contraindicationsand intolerance were not considered. We suggest referringto the 2008 ACR recommendations for the use of DMARDsin rheumatoid arthritis (19) for general guidance aboutmedication contraindications. Tapering or discontinua-tion of medications for patients with inactive disease wasalso not considered. Only the most relevant and frequentlyused agents within each medication class were included,as determined using a structured iterative process via elec-tronic mail with repeated revisions to the proposed listuntil it was accepted by all CEP members. Agents notwidely commercially available for the treatment of JIA atthe time of the literature search (e.g., canakinumab, rilona-cept, tocilizumab) were excluded. The indications for sys-temic glucocorticoids for the treatment of synovitis werenot considered, owing to a lack of published evidence. Thetreatment of uveitis, enthesitis, and macrophage activationsyndrome was not considered.

Systematic literature review. The systematic literaturereview was restricted to publications available in Medline.Briefly, we searched using PubMed for articles in English,with abstracts, and published from 1966 to the present.The final search strategy, developed in consultation with avirtual reference librarian, is shown in SupplementaryAppendix A (available in the online version of this articleat http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2151-4658). We performed the final search on March 3,2009, and identified 756 articles for further consideration.

We next performed title and abstract review of the iden-tified articles. In keeping with the scope of the recommen-dations, all studies that did not explicitly address anypharmacotherapeutic clinical outcomes of the medicationsof interest were excluded (e.g., radiographic descriptivestudies, pharmacokinetics, genomics, etc.). Because of the

relatively small number of identified articles, we includeduncontrolled studies, regardless of the number of patientsreported. Review articles were excluded. Two reviewersreviewed all of the abstracts for inclusion, blinded to eachother’s determinations. Disagreement was resolved by athird reviewer (ST-R) and confirmed by a fourth reviewer(TB), when necessary. Following title and abstract review,239 articles remained for consideration.

Each of the full-length articles was abstracted by one of ateam of reviewers with key elements from each articleentered into an electronic database. Articles were ex-cluded during the full-length article review when no phar-macotherapeutic clinical outcomes of medications of in-terest were identified; all of these exclusions were verifiedby a second reviewer (TB). As a result, 214 articles wereincluded in the final comprehensive evidence report thatwas presented to the TFP prior to the first round of voting.

An identical literature search was repeated on October5, 2009, to identify any new publications since the firstsystematic review. Thirty new articles were identified andsubjected to the same review process as the initial search.Seven fully abstracted articles were added to the updatedevidence report and presented to the TFP prior to theface-to-face meeting.

Scenario definitions. In order to develop clinical sce-narios in accordance with the RAND/UCLA Appropriate-ness Method (18), several key clinical decision parameterswere deemed necessary by the CEP: disease phenotype,prognostic features, disease activity, and current therapy.Definitions and values for these key parameters were asevidence based as possible and were determined using astructured iterative process via electronic mail with re-peated revisions to the proposed parameters until theywere accepted by all CEP members.

JIA treatment groups. Chronic childhood arthritis is aheterogeneous condition. The most recent ILAR diseaseclassification criteria (1) divide JIA into 6 distinct catego-ries. However, this disease classification system was notstrictly applied to the development of these recommenda-tions for two reasons: currently, there is minimal evidenceto support the differential treatment of children with JIAfor many of the category distinctions, and the inclusion ofall 6 categories would unnecessarily increase the totalnumber of scenarios to an unmanageable number for con-sideration by the TFP (18).

In place of the ILAR JIA classification, the CEP devel-oped “treatment groups” for these recommendations withthe goal of succinctly representing clinical decision mak-ing in the treatment of JIA. The JIA category of systemicarthritis proved to be especially challenging to evaluate.Attempts to exhaustively depict the myriad possible clin-ical presentations of systemic arthritis were impractical.Therefore, recommendations for the treatment of signifi-cant active systemic features (e.g., fever) and active arthri-tis for patients with systemic arthritis were consideredseparately and independently by the TFP. Other authorshave suggested this dichotomy when considering thera-peutic choices for systemic arthritis (22). The appropriatetreatment of systemic arthritis patients with concurrently

ACR 2011 Recommendations for the Treatment of JIA 467

active systemic features and active arthritis may be ex-pected to incorporate elements of both sets of recommen-dations, but this was not explicitly considered by the TFP.The 5 JIA treatment groups used in these recommenda-tions are described below.

History of arthritis of 4 or fewer joints. This group in-cludes patients with the ILAR categories of persistent oli-goarthritis, as well as patients with psoriatic arthritis, en-thesitis-related arthritis, and undifferentiated arthritiswho have developed active arthritis in only 4 or fewerjoints in total throughout the history of their diseasecourse. Patients who currently have 4 or fewer activejoints, but who have a history of 5 or more active joints intotal, are considered in the “history of arthritis of 5 or morejoints” treatment group. Patients with systemic arthritis oractive sacroiliac arthritis are considered in separate treat-ment groups.

History of arthritis of 5 or more joints. This group in-cludes patients with the ILAR categories of extended oli-goarthritis, rheumatoid factor (RF)–negative polyarthritis,RF-positive polyarthritis, as well as patients with psoriaticarthritis, enthesitis-related arthritis, and undifferentiatedarthritis who have developed active arthritis in 5 or morejoints in total throughout the history of their disease. Pa-tients in this group need not currently have 5 or moreactive joints. Patients with systemic arthritis or active sac-roiliac arthritis are considered in separate treatment groups.

Active sacroiliac arthritis. This group includes all pa-tients with clinical and imaging evidence of active sacro-

iliac arthritis. This group is anticipated to include primar-ily patients with the ILAR categories of enthesitis-relatedarthritis and psoriatic arthritis, but may include patientsfrom any of the ILAR JIA categories.

Systemic arthritis with active systemic features (andwithout active arthritis). This group includes all patientswho fulfill the ILAR criteria for systemic arthritis and whohave active fever of systemic JIA with or without othersystemic features, but without active arthritis. An exampleof this clinical phenotype would be a patient whose arthri-tis resolved spontaneously or rapidly upon initiation ofNSAIDs but who had persistent fever.

Systemic arthritis with active arthritis (and without ac-tive systemic features). This category includes all patientswho fulfill the ILAR criteria for systemic arthritis and whohave active arthritis, but without active systemic features.An example of this clinical phenotype would be a patientwhose systemic features resolved spontaneously or rap-idly upon initiation of NSAIDs but whose arthritis re-mained active.

Features of poor prognosis. Risk stratification is crucialfor guiding optimal treatment. The prognosis for patientswith JIA is variable, and some clinical factors have beenshown to predict worse outcomes. The CEP considered thepublished literature and their personal clinical experiencein developing the features of poor prognosis for theserecommendations.

Each JIA treatment group has its own respective featuresof poor prognosis. In each case, the presence of one listed

Table 1. Features of poor prognosis and disease activityfor a history of arthritis of 4 or fewer joints

FEATURES OF POOR PROGNOSIS (must satisfy 1)Arthritis of the hip (23–25) or cervical spineArthritis of the ankle (25–27) or wrist (26,28) AND

marked (29) or prolonged (23,25,26,29,30)inflammatory marker elevation

Radiographic damage (erosions or joint spacenarrowing by radiograph) (31)

DISEASE ACTIVITY LEVELSLow disease activity (must satisfy all)

1 or fewer active jointsErythrocyte sedimentation rate or C-reactive protein

level normalPhysician global assessment of overall disease

activity �3 of 10Patient/parent global assessment of overall well-being

�2 of 10Moderate disease activity (does not satisfy criteria

for low or high activity)1 or more features greater than low disease activity

level AND fewer than 3 features of high diseaseactivity

High disease activity (must satisfy at least 3)2 or more active jointsErythrocyte sedimentation rate or C-reactive protein

level greater than twice upper limit of normalPhysician global assessment of overall disease


�4 of 10

Table 2. Features of poor prognosis and disease activityfor a history of arthritis of 5 or more joints

FEATURES OF POOR PROGNOSIS (must satisfy 1)Arthritis of the hip (23–25) or cervical spinePositive rheumatoid factor (5,23,28,30,32,33) OR anti–

cyclic citrullinated peptide (33,34) antibodiesRadiographic damage (erosions or joint space

narrowing by radiograph) (31)





�2 of 10Moderate disease activity (does not satisfy criteria for

low or high activity)1 or more features greater than low disease activity





�5 of 10

468 Beukelman et al

feature is sufficient to classify the patient as having a poorprognosis for the purposes of these recommendations. Amore complex approach to features of poor prognosiswould have increased the number of scenarios to an un-manageable number for consideration by the TFP (18). Thefeatures of poor prognosis (and their corresponding liter-ature references) are listed according to each JIA treatmentgroup in Tables 1–5. Of note, the CEP believed there wasinsufficient published evidence available to include dam-age detected by imaging other than radiographs as a featureof poor prognosis in JIA.

JIA disease activity. Recommendations require cleardefinitions of disease activity to make rational therapeuticchoices. In these recommendations, “active joints” and“active arthritis” are defined by joints with swelling notdue to deformity or joints with limitation of motion and

with pain or tenderness (10). “Active fever” means currentfever that is attributable to systemic arthritis disease activ-ity. At least one continuous measure of JIA disease activityhas been recently developed (39). Nevertheless, currentlyno continuous disease activity measures have been exten-sively validated or widely applied to daily clinical prac-tice. Accordingly, the CEP developed levels of diseaseactivity for these recommendations that are specific toeach treatment group and with the goal of succinctly cap-turing clinical decision making. It should be noted thatthese disease activity levels are subjective and not strictlyevidence based. However, the creation of discrete diseaseactivity levels was requisite for the effective use of theRAND/UCLA Appropriateness Method.

These recommendations are based on 3 disease activitylevels: low, moderate, and high. Patients with inactivedisease were not considered. In a broad sense, the lowdisease activity level is meant to represent patients at thelowest disease activity level for which a majority of clini-cians may consider altering the current medication regi-men, and the high disease activity level is meant to repre-sent patients with disease activity that is equivalent to orhigher than the “average” subject that may have beenenrolled in a clinical trial of the medications under con-sideration. The CEP considered baseline patient data fromrecently published clinical trials (10,15,17,40–42), datafrom a recent attempt to define minimal disease activity inJIA (43), and their personal clinical experience in devel-oping the disease activity levels for these recommenda-tions. The disease activity levels are listed according toeach JIA treatment group in Tables 1–5.

Table 3. Feature of poor prognosis and disease activityfor active sacroiliac arthritis

FEATURE OF POOR PROGNOSISRadiographic damage of any joint (erosions or joint

space narrowing by radiograph)


Normal back flexionErythrocyte sedimentation rate or C-reactive protein






High disease activity (must satisfy at least 2)Erythrocyte sedimentation rate or C-reactive protein

greater than twice upper limit of normalPhysician global assessment of overall disease


�4 of 10

Table 4. Features of poor prognosis and disease activityfor systemic arthritis with active systemic features (and

without active arthritis)

FEATURES OF POOR PROGNOSIS6-month duration of significant active systemic disease,

defined by: fever (35–37), elevated inflammatorymarkers (35–37), or requirement for treatment withsystemic glucocorticoids (36)

DISEASE ACTIVITY LEVELS (2 levels)Active fever AND physician global assessment of

overall disease activity �7 of 10Active fever AND systemic features of high disease

activity (e.g., significant serositis) that result inphysician global assessment of overall diseaseactivity �7 of 10

Table 5. Features of poor prognosis and disease activityfor systemic arthritis with active arthritis (and without

active systemic features)

FEATURES OF POOR PROGNOSIS (must satisfy 1)Arthritis of the hip (38)Radiographic damage (erosions or joint space

narrowing by radiograph) (31)











�5 of 10


During the evaluation of the clinical scenarios, TFPmembers were allowed to recommend continuation of cur-rent therapy (not initiate a new therapeutic agent), regard-less of the current disease activity level. In addition to apatient’s current disease activity level, clinicians in prac-tice may consider a patient’s disease activity level prior toinitiating the current treatment regimen when evaluatingthe effectiveness of the current treatment. That is, a currentstate of low disease activity may represent a recent majorimprovement for one patient and no improvement for an-other. Due to the complexity and number of clinical sce-narios, previous disease activity levels were not includedin the recommendation process and TFP members consid-ered the appropriateness of initiating new therapeuticagents based on a patient’s current disease activity levelonly.

Therapeutic agent definitions. Medication classes usedin the recommendation scenarios are defined as follows:NSAID refers to all nonsteroidal antiinflammatory drugsused commonly in clinical practice in the US and includesselective cyclooxygenase 2 inhibitors but not aspirin. Cal-cineurin inhibitors refer to cyclosporine and tacrolimus.Tumor necrosis factor � (TNF�) inhibitors refer to adali-mumab, etanercept, and infliximab.

Clinical evaluation of the effectiveness of a given thera-peutic agent may depend on the dose received. For allrecommendations, it is assumed that patients have re-ceived the maximum tolerated typical dose of prior med-ications, as listed in Supplementary Appendix B (availablein the online version of this article at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2151-4658). Of note,the dose of methotrexate was assumed to be 15 mg/m2

(0.6 mg/kg) and administered via the parenteral route.These specific doses were used as a guide for TFP mem-bers when considering the scenarios; higher doses of thesetherapeutic agents may be appropriate in some clinicalsituations.

Clinical evaluation of the effectiveness of a given thera-peutic agent may depend on the duration of therapy. Somescenarios explicitly stated the duration of the current treat-ment regimen. In scenarios where duration of therapy wasnot defined, it was assumed that the duration of therapywas sufficiently long to assess the response to therapy.

The recommendations assume that all medication regi-mens may contain a single NSAID as adjunct therapywhen considering the appropriateness of initiating newtherapies. For example, a patient described as currentlyreceiving methotrexate is assumed to be taking methotrex-ate with concurrent use of a single NSAID, as appropriate.

Many of the recommendations refer to “initiating” a newtherapy for patients presently undergoing treatment forJIA. In these cases, “initiating” is defined as either addingthe new therapy while continuing current therapy orswitching to the new therapy while discontinuing the cur-rent therapy. To limit the total number of scenarios, wemade no distinction between adding and switching forsome of the recommendations. Of note, combination bio-logic DMARD therapy was not considered by these recom-mendations, owing to concern from the reported increasedincidence of infections in studies of rheumatoid arthritis

in adult populations (44,45). Accordingly, initiation of anew biologic DMARD is always intended to be accompa-nied by discontinuation of any current biologic DMARD.

Safety monitoring. Scenarios were created to evaluatethe appropriateness of several safety monitoring interven-tions for selected therapeutic agents and were voted uponby the TFP in the same manner as the treatment scenarios.

RAND/UCLA Appropriateness Method voting and scor-ing. A teleconference was conducted to orient all TFPmembers to the voting task. Individual scenarios con-tained an explicit question that incorporated the key clin-ical parameters described above (e.g., “Rate the appropri-ateness of initiating TNF� inhibitor in a patient with ahistory of arthritis of 5 or more joints who has receivedmethotrexate for 6 months and has moderate disease ac-tivity and features of poor prognosis”). There were 1,539such individual scenarios and each TFP member evalu-ated all of them.

Each scenario was evaluated for “appropriateness,”which is defined as “the health benefits exceed the healthrisks by a sufficiently wide margin that the intervention isworth doing” (18). In this evaluation, the risks of initiatinga particular therapeutic agent include the risk of not initi-ating an alternative agent (e.g., the risk of initiating NSAIDmonotherapy includes the risk of not initiating methotrex-ate with its greater potential for therapeutic benefit). TheTFP scored each scenario on a 9-point scale, with scores of7–9 denoting “appropriate,” 1–3 denoting “inappropri-ate,” and 4–6 denoting “uncertain,” i.e., either the risksand benefits are approximately equal or not enough infor-mation is available to make a meaningful evaluation. TFPmembers cast their votes while taking into account thecurrently available published literature (including but notlimited to that provided to them in the evidence report)and their own personal clinical experience. Votes werecast independently by entering them into a formatted elec-tronic spread sheet. The voting sheets were then electron-ically collected and combined to analyze the results.

The votes were analyzed in accordance with the RAND/UCLA Appropriateness Method (18), taking into accountboth the distribution and the median value of the votes.The scenario votes were first evaluated for disagreement(wide dispersion of votes), defined as one-third or more ofthe TFP assigning a score of inappropriate (1, 2, or 3),while one-third or more of the TFP assigned the samescenario a score of appropriate (7, 8, or 9). In the absenceof disagreement, a median score of 3 or less classified ascenario as “inappropriate,” and a median rating of 7 orgreater classified a scenario as “appropriate.” Those sce-narios with median ratings in the 3.5 to 6.5 range, togetherwith those where disagreement occurred, were classifiedas “uncertain.”

Following analysis of the first round of voting, a subse-quent face-to-face meeting of the TFP was conducted anddiscussion was focused on scenarios where the votingoutcome was “uncertain.” Following sufficient discussionon each group of scenarios, the TFP members voted for thefinal time. No attempts were made to “force” consensusamong the TFP. Rather, the RAND/UCLA AppropriatenessMethod largely seeks to identify existing consensus (18).

470 Beukelman et al

Developing recommendations from votes. Statementslisted as recommendations met the RAND/UCLA Appro-priateness Method criteria for “appropriate” in the finalTFP votes with no wide dispersion of votes and a medianscore in the appropriate range (7 to 9). In some instances,more than one individual therapeutic agent was recom-mended for a given combination of clinical parameters;these are noted as being “recommended as one treatmentapproach.” Indications for initiating therapeutic agentsthat did not meet the criteria for appropriate were summa-rized as either uncertain or inappropriate. In these sum-mary statements, uncertain means that some or all of thescenarios met the definition of “uncertain” and some ornone of the scenarios met the definition of “inappropri-ate.” Inappropriate means that all of the scenarios met thedefinition of “inappropriate” and none met the definitionof “uncertain.” The recommendations were reviewed indetail by all CEP members to ensure proper and cleartranslation of the TFP votes into text.

During the face-to-face discussion of the scenarios, sev-eral points were raised that the TFP members believedshould be mentioned in the recommendations, eventhough they were not addressed in the voting scenarios.Following discussion, consensus on these points wasreached through a simple show of hands vote. These state-ments are clearly noted in the results, are not consideredformal recommendations, and were not assigned a level ofevidence.

Rating evidence for recommendations. For each finalrecommendation of appropriate or inappropriate, a level ofevidence was assigned based on the methods of the Uni-versity of Oxford Centre for Evidence-Based Medicine, UK(46). This categorization of evidence was used in the re-cently published European League Against Rheumatismrecommendations for the management of rheumatoid ar-thritis (47) and incorporates the concept of “extrapola-tions,” where published data are used in a situation thathas potentially clinically important differences from theoriginal study situation. Such situations are frequentlyencountered when the patient’s clinical factors in a rec-ommendation do not match exactly with those of the sup-porting studies (19). The Oxford system also distinguishesbetween recommendations for which there is low-gradeevidence and those for which there is an absence of pub-lished evidence.

Level of evidence “A” was assigned when the recom-mendation was supported by randomized clinical trials (orconsistent inception cohort studies for questions of prog-nosis). Level of evidence “B” was assigned when the rec-ommendation was supported by nonrandomized con-trolled studies (e.g., cohort and case–control studies) orextrapolations from randomized clinical trials. Level ofevidence “C” was assigned when the recommendation wassupported by uncontrolled studies (case series), extrapo-lations from nonrandomized controlled studies, or markedextrapolations from randomized clinical trials (e.g., stud-ies of adult arthritis patients applied to juvenile arthritis orstudies of polyarthritis phenotype applied to oligoarthri-tis). Level of evidence “D” was assigned when the recom-

mendation was based on expert opinion without support-ing published evidence.

Managing perceived potential conflicts of interest. Per-ceived potential conflicts of interest were managed in aprospective and structured manner. All members of theCEP and TFP completed and submitted the ACR disclo-sure of interest form prior to participation in the project.The forms were updated prior to the face-to-face meeting.A summary listing of all perceived potential conflicts ofinterest was distributed to all project participants and wassubmitted for publication along with these recommenda-tions.

Peer review of recommendations. Following submis-sion of the draft recommendations, the ACR invited peerreview by members of the ACR Practice Guidelines Sub-committee, the ACR Quality of Care Committee, and theACR Board of Directors. The recommendations were ulti-mately subject to the regular review process of this journal.

Updates to ACR recommendations. We expect thatknowledge of the appropriate therapeutic management ofJIA will continue to advance. Clearly, these ACR recom-mendations will require updating to remain accurate andrelevant. We suggest that approximately 3 years after theinitiation of this current project (i.e., in 2012), the ACRPractice Guidelines Subcommittee and the ACR Quality ofCare Committee evaluate newly published evidence andsolicit expert opinion on the need for revision of theserecommendations. Targeted updates focused only on areasof new published evidence may be appropriate.

Future research in the treatment of JIA may reasonablybe directed by knowledge deficiencies identified by theserecommendations. Of particular note to the CEP was theneed for comparative long-term studies of the benefits andrisks of early initiation of biologic therapies, developmentand implementation of continuous disease activity scoresin clinical practice, studies of the evaluation and manage-ment of enthesitis, studies of the management of systemicarthritis and macrophage activation syndrome, and studiesof the appropriate management of patients with inactivedisease while receiving therapy.

RESULTS

Each ACR recommendation for the treatment of JIA isfollowed by the assigned level of evidence and the corre-sponding publication citations.

General medication usage. The TFP considered thegeneral usage of intraarticular glucocorticoid injectionsand the use of methotrexate when initiating TNF� inhibi-tors. These recommendations apply broadly across treat-ment groups.

Glucocorticoid joint injections. The use of glucocorti-coid joint injections for active arthritis was recommended,regardless of concurrent therapy (no DMARD, nonbiologicDMARD, or biologic DMARD) or JIA treatment group (levelC) (48–65). Glucocorticoid joint injections should be per-formed with triamcinolone hexacetonide, owing to its


demonstrated superior efficacy (level A) (52,53). Intraar-ticular glucocorticoid injections are expected to result inclinical improvement of arthritis for at least 4 months(level A) (49–66). A shorter duration of clinical responsemay imply a need for escalation of systemic therapy. In-traarticular glucocorticoid injections that result in clinicalimprovement of arthritis for at least 4 months may berepeated as needed (level B) (50,53,57,64,65).

Methotrexate with TNF� inhibitors. Continuing metho-trexate when initiating a TNF� inhibitor (etanercept oradalimumab) was recommended for patients who had apartial previous clinical response to methotrexate (level B)

(67). The TFP did not reach agreement on continuing ordiscontinuing methotrexate when initiating a TNF� inhib-itor (etanercept or adalimumab) for patients who had apoor previous clinical response to methotrexate. The ap-propriateness of continuing methotrexate when initiatinginfliximab was assumed and was not evaluated by the TFP,owing to the recognized potential for methotrexate to re-duce the incidence of neutralizing antibodies to infliximab(68) and consistent with the labeling of infliximab (69).

Initiation of therapeutic agents. The appropriateness ofinitiating various therapeutic agents in the treatment of JIA

Figure 1. Treatment recommendations for patients with a history of arthritis of 4 or fewerjoints. These recommendations are intended for patients with juvenile idiopathic arthritis(JIA) who have only developed active arthritis in 4 or fewer joints in total throughout thehistory of their disease course and are based upon duration of current therapy, diseaseactivity, and features of poor prognosis. If criteria for escalation of therapy are not met, thencontinue current therapy along with adjunct nonsteroidal antiinflammatory drugs (NSAIDs)or glucocorticoid joint injections, as needed. Recommendations for reduction of therapy arenot addressed. See Table 1 for definitions of disease activity and features of poor prognosis.* � sulfasalazine may be an appropriate treatment for patients with the enthesitis-relatedarthritis category of JIA (see text for details); MTX � methotrexate; TNF� � tumor necrosisfactor �.

472 Beukelman et al

is organized by treatment group. Each recommendation ischaracterized by the patient’s clinical factors: treatmentgroup, current medication, disease activity, and features ofpoor prognosis. Individual therapeutic agents are listed inthe order of escalation of therapy as determined by theTFP. In situations where two or more agents were recom-mended for similar patient clinical factors, the agents arelisted alphabetically. The recommendations are not mutu-ally exclusive, i.e., the initiation of more than one thera-peutic agent may be appropriate for a given set of patientclinical factors due to overlapping indications. Therapeu-tic agents that were considered by the TFP but not recom-mended for initiation are listed at the end of each treat-ment group in alphabetical order.

History of arthritis of 4 or fewer joints. The definitionsof disease activity and features of poor prognosis for thistreatment group are listed in Table 1. A diagram of theoverall treatment strategy is shown in Figure 1.

NSAID monotherapy. Initiation of NSAID monotherapy(without glucocorticoid joint injection) was recommendedas one treatment approach for patients with low diseaseactivity, without joint contracture, and without features ofpoor prognosis (level B) (70–76). Continuation of NSAIDmonotherapy (without additional therapy) for longer than2 months was inappropriate for patients with active arthri-tis, irrespective of poor prognostic features.

Intraarticular glucocorticoid injections. Intraarticularglucocorticoid injections (with or without additional ther-apy) were recommended for all patients with active arthri-tis, irrespective of disease activity level, prognostic fea-tures, or joint contracture (level C) (48–66). As statedabove, glucocorticoid joint injections should be performedwith triamcinolone hexacetonide (level A) (52) and areexpected to result in clinical improvement of arthritis forat least 4 months (level A) (49–66). A shorter duration ofclinical improvement may imply a need for escalation ofsystemic therapy. Glucocorticoid injections that result inclinical improvement of arthritis for at least 4 months maybe repeated as needed (level B) (50,53,57,64,65).

Methotrexate. Initiation of methotrexate was recom-mended as initial treatment (without prior therapy) forpatients with high disease activity and features of poorprognosis (level C) (40,77–83). Following initial glucocor-ticoid joint injection(s), initiation of methotrexate was rec-ommended for patients with high disease activity withoutfeatures of poor prognosis and for patients with moderatedisease activity and features of poor prognosis (level C)(40,77–83). Following repeated glucocorticoid injections,initiation of methotrexate was recommended for patientswith moderate disease activity without features of poorprognosis and for patients with low disease activity andfeatures of poor prognosis (level C) (40,77–83).

Sulfasalazine. Initiation of sulfasalazine was recom-mended following glucocorticoid joint injection or an ad-equate trial of NSAIDs for patients with the enthesitis-related arthritis category of JIA with moderate or highdisease activity, irrespective of features of poor prognosis(level B) (84). Initiation of sulfasalazine was uncertain forpatients who are not diagnosed with the enthesitis-relatedarthritis category of JIA.

TNF� inhibitors. Initiation of a TNF� inhibitor was rec-ommended for patients who have received glucocorticoidjoint injections and 3 months of methotrexate at the max-imum tolerated typical dose and have moderate or highdisease activity and features of poor prognosis (level C)(10,15). Initiation of a TNF� inhibitor was also recom-mended for patients who have received glucocorticoidjoint injections and 6 months of methotrexate and havehigh disease activity without features of poor prognosis(level C) (10,15).

Additionally, initiation of a TNF� inhibitor was recom-mended for patients specifically with the enthesitis-re-lated arthritis category of JIA who have received glucocor-ticoid joint injections and an adequate trial ofsulfasalazine (without prior methotrexate) and have mod-erate or high disease activity, irrespective of prognosticfeatures (level C) (11,85).

Abatacept. Initiation of abatacept was uncertain prior toinitiation of a TNF� inhibitor.

Hydroxychloroquine. Initiation of hydroxychloroquinemonotherapy (with or without concurrent NSAIDs) wasinappropriate for patients with active arthritis (level C)(86).

Leflunomide. Initiation of leflunomide was uncertain.Nonbiologic DMARD combinations. Initiation of non-

biologic DMARD combinations (methotrexate plus sul-fasalazine and/or hydroxychloroquine) was uncertain.

History of arthritis of 5 or more joints. The definitionsof disease activity and features of poor prognosis for thistreatment group are listed in Table 2. A diagram of theoverall treatment strategy is shown in Figure 2.

NSAID monotherapy. Initiation of NSAID therapy alone(monotherapy without glucocorticoid joint injection) wasuncertain for patients with active arthritis. Continuation ofNSAID monotherapy for longer than 2 months was inap-propriate for patients with active arthritis, irrespective ofpoor prognostic features (level C) (80,87).

Methotrexate. Initiation of methotrexate was recom-mended as initial treatment for patients with high diseaseactivity, irrespective of poor prognostic factors, and forpatients with moderate disease activity and features ofpoor prognosis (level B) (40,77–80). Following approxi-mately 1 month of NSAIDs, initiation of methotrexate wasrecommended for patients with low disease activity andfeatures of poor prognosis (level B) (40,77–80). Followingapproximately 1 to 2 months of NSAIDs, initiation ofmethotrexate was recommended for patients with moder-ate disease activity without features of poor prognosis(level B) (40,77–80).

Leflunomide. The TFP generally favored the use ofmethotrexate over leflunomide, owing to greater personaland collective experience with methotrexate. However,initiation of leflunomide was recommended as one treat-ment approach as initial treatment for patients with highdisease activity and features of poor prognosis (level B)(77). Following a brief trial of NSAIDs, initiation of le-flunomide was recommended as one treatment approachfor patients with high disease activity without features ofpoor prognosis and for patients with moderate diseaseactivity with features of poor prognosis (level B) (77).


TNF� inhibitors. Initiation of a TNF� inhibitor was rec-ommended for patients who have received methotrexate orleflunomide for 3 months at the maximum tolerated typi-cal dose and have moderate or high disease activity, irre-spective of poor prognostic features (level B) (10,15). Ini-tiation of a TNF� inhibitor was also recommended forpatients who have received methotrexate or leflunomidefor 6 months and have low disease activity, irrespective ofpoor prognostic features (level B) (10,15).

Switching from one TNF� inhibitor to another was rec-ommended as one treatment approach for patients whohave received the current TNF� inhibitor for 4 months andhave moderate or high disease activity, irrespective of poorprognostic features (level C) (88,89). Switching to a TNF�

inhibitor was recommended as one treatment approach forpatients who have received abatacept for 3 months andhave high disease activity and features of poor prognosisand for patients who have received abatacept for 6 monthsand have moderate or high disease activity, irrespective ofprognostic features (level D).

Abatacept. Initiation of abatacept was recommended asone treatment approach for patients who have received aTNF� inhibitor for 4 months and have high disease activ-ity, irrespective of features of poor prognosis, or moderatedisease activity and features of poor prognosis (level B)(17). Initiation of abatacept was recommended as one treat-ment approach for patients who have received more thanone TNF� inhibitor sequentially and have moderate or

Figure 2. Treatment recommendations for patients with a history of arthritis of 5 or morejoints. These recommendations are intended for patients with juvenile idiopathic arthritiswho have developed active arthritis in 5 or more joints in total throughout the history of theirdisease and are based upon duration of current therapy, disease activity, and features of poorprognosis. If criteria for escalation of therapy are not met, then continue current therapyalong with adjunct nonsteroidal antiinflammatory drugs (NSAIDs) or glucocorticoid jointinjections, as needed. Recommendations for reduction of therapy are not addressed. SeeTable 2 for definitions of disease activity and features of poor prognosis. * � leflunomidemay be an appropriate treatment alternative (see text for details); MTX � methotrexate;TNF� � tumor necrosis factor �.

474 Beukelman et al

high disease activity, irrespective of poor prognostic fea-tures, or low disease activity with features of poor prog-nosis (level B) (17).

Rituximab. Initiation of rituximab was recommended asone treatment approach for patients who have received aTNF� inhibitor and abatacept sequentially and have highdisease activity, irrespective of poor prognostic features, orhave moderate disease activity and features of poor prog-nosis (level C) (90–92). Although not formally assessedusing the RAND/UCLA Appropriateness Method, therewas consensus among the TFP that rituximab may be moreappropriate for patients who test positive for RF comparedto patients who do not.

Anakinra. Initiation of anakinra was uncertain.Hydroxychloroquine. Initiation of hydroxychloroquine

monotherapy (with or without concurrent NSAIDs) wasinappropriate for patients with active arthritis (level A) (86).

Sulfasalazine. Initiation of sulfasalazine was uncertain.Patients with the enthesitis-related arthritis category of JIAand history of arthritis of 5 or more joints were not inde-pendently considered by the TFP.

Nonbiologic DMARD combinations. Initiation of non-biologic DMARD combinations (methotrexate plus sul-fasalazine and/or hydroxychloroquine) was uncertain. Asstated in Materials and Methods, intolerance of or contra-indications to biologic DMARD therapies were not consid-ered by the TFP.

Active sacroiliac arthritis. As stated in Materials andMethods, active sacroiliac arthritis was defined by thepresence of clinical and imaging evidence. The definitionsof disease activity and features of poor prognosis for thistreatment group are listed in Table 3. The only medicationclass evaluated by the TFP for this treatment group was theTNF� inhibitors. There is no corresponding figure for thistreatment group.

TNF� inhibitors. In general, initiation of a TNF� inhib-itor was recommended more readily for patients with ac-tive sacroiliac arthritis than for patients without this jointaffected. Initiation of a TNF� inhibitor was recommendedfor patients with active sacroiliac arthritis who have re-ceived an adequate trial of NSAIDs and have high diseaseactivity and features of poor prognosis (level C) (93,94).Initiation of a TNF� inhibitor was also recommended forpatients who have received 3 months of methotrexate andhave high disease activity, irrespective of prognostic fac-tors, or moderate disease activity with features of poorprognosis, or 6 months of methotrexate and moderate dis-ease activity without features of poor prognosis (level C)(93,94). Also recommended was initiation of a TNF� in-hibitor for patients who have received 3 months of sul-fasalazine and have moderate or high disease activity,irrespective of prognostic features, or 6 months of sul-fasalazine and low disease activity with features of poorprognosis (level C) (93,94).

Systemic arthritis. As noted in Materials and Methods,the JIA category of systemic arthritis was divided into twotreatment groups: active systemic features and active ar-thritis. The appropriate treatment of patients with concur-

rent active systemic features and active arthritis may beexpected to incorporate elements of both sets of recom-mendations. Given the variable course of systemic arthritisand the extent to which the prior disease course mayinfluence subsequent treatment decisions, the TFP evalu-ated the appropriateness of initiating therapies for recentlydiagnosed patients, as opposed to patients with extensiveand potentially influential disease histories.

As noted in Materials and Methods, the initiation oftreatment with interleukin-6 inhibitors (such as tocili-zumab) or interleukin-1 inhibitors other than anakinra(such as canakinumab or rilonacept) was not considered inthe development of these recommendations because thesetherapeutic agents were not widely commercially avail-able at the time. Options for the treatment of systemicarthritis appear to be increasing. The appropriateness ofinitiating recently available therapeutic agents for thetreatment of systemic arthritis may need to be the focus ofa timely update to these recommendations.

Systemic arthritis with active systemic features (andwithout active arthritis). The definitions of disease activ-ity and features of poor prognosis for this treatment groupare listed in Table 4. A diagram of the overall treatmentstrategy is shown in Figure 3.

These recommendations are not meant to apply to pa-tients with clinical and laboratory evidence of macrophageactivation syndrome that warrants specific modification oftherapy. Life-threatening clinical scenarios (e.g., cardiactamponade) were not considered by the TFP and maywarrant deviation from these recommendations. TNF� in-hibitors were not considered by the TFP in the treatment ofactive systemic features, owing to their reported relativelypoor effectiveness (12,89,95–98).

NSAID monotherapy. Although not formally assessedusing the RAND/UCLA Appropriateness Method, therewas consensus among the TFP that the use of NSAIDmonotherapy is appropriate during the clinical evaluationof possible systemic arthritis. The following recommenda-tions apply to patients who have been diagnosed withsystemic arthritis.

The initiation (or continuation) of NSAID monotherapywas uncertain for patients with active fever. Initiation ofNSAID monotherapy was inappropriate for patients withactive fever and physician global assessment of overalldisease activity (MD global) of �7 of 10 (level D). Contin-uation of NSAID monotherapy for a duration greater than1 month was inappropriate for patients with active fever(level C) (99).

Systemic glucocorticoids. Owing to a near completelack of published evidence, specific systemic glucocorti-coid doses or routes of administration were not consideredby the TFP.

Initiation of systemic glucocorticoids (with or withoutadditional concurrent therapy) was recommended as ini-tial therapy for patients with active fever and MD global of�7 (level D). Initiation of systemic glucocorticoids follow-ing up to 2 weeks of NSAIDs was recommended for allpatients with active fever (level C) (99,100).

Anakinra. Initiation of anakinra was recommended forall patients with active fever and features of poor progno-sis, irrespective of current therapy (level C) (101). Initia-


tion of anakinra was recommended for all patients whosustain or develop active fever while receiving systemicglucocorticoids (level C) (16,101–103).

Calcineurin inhibitors. Initiation of calcineurin inhibi-tors for patients with active fever and without active ar-thritis was uncertain for initial management.

Intravenous immunoglobulin. Initiation of intravenousimmunoglobulin for patients with active fever and withoutactive arthritis was uncertain for initial management.

Methotrexate. Initiation of methotrexate was inappro-priate for initial management of patients with active feverand without active arthritis (level B) (78).

Thalidomide. Initiation of thalidomide for patients withactive fever and without active arthritis was uncertain forinitial management.

Systemic arthritis with active arthritis (and withoutactive systemic features). The definitions of disease activ-ity and features of poor prognosis for this treatment groupare listed in Table 5. A diagram of the overall treatmentstrategy is shown in Figure 4. Consistent with the assess-ment of other treatment groups, the appropriateness ofsystemic glucocorticoids for the treatment of arthritis inpatients with systemic arthritis was not addressed.

Figure 3. Treatment recommendations for patients with systemic arthritis and active sys-temic features (and without active arthritis). These recommendations are intended forpatients with juvenile idiopathic arthritis who have systemic arthritis with active systemicfeatures and without active arthritis. Recommendations are based upon duration of currenttherapy, disease activity, and features of poor prognosis. If criteria for escalation of therapyare not met, then continue current therapy along with adjunct nonsteroidal antiinflamma-tory drugs (NSAIDs), as needed. Recommendations for reduction of therapy are not ad-dressed. See Table 4 for definitions of disease activity and features of poor prognosis. MDGlobal � physician global assessment of overall disease activity (range 0–10).

476 Beukelman et al

NSAID monotherapy. Initiation of NSAID monotherapy(with or without glucocorticoid joint injections) was rec-ommended for patients with low disease activity withoutfeatures of poor prognosis (level B) (70). It was presumedthat most patients with newly diagnosed systemic arthritiswould have received NSAIDs during their diagnostic eval-uation. Continuation of NSAID monotherapy (without sys-temic therapy) for a duration greater than 1 month wasuncertain for patients with any level of disease activity,irrespective of poor prognostic features (level D).

Methotrexate. Initiation of methotrexate was recom-mended for all patients with active arthritis following 1month or less of NSAID monotherapy (with or withoutglucocorticoid joint injections), irrespective of poor prog-nostic features (level B) (40,79).

Anakinra. Initiation (addition) of anakinra was recom-mended for patients who have received methotrexate andwho have moderate or high disease activity, irrespective offeatures of poor prognosis (level C) (16,101–104). Initiationof anakinra was also recommended for patients who have

Figure 4. Treatment recommendations for patients with systemic arthritis and active arthri-tis (and without active systemic features). These recommendations are intended for patientswith juvenile idiopathic arthritis who have systemic arthritis with active arthritis andwithout active systemic features. Recommendations are based upon duration of currenttherapy, disease activity, and features of poor prognosis. If criteria for escalation of therapyare not met, then continue current therapy along with adjunct nonsteroidal antiinflamma-tory drugs (NSAIDs), as needed. Recommendations for reduction of therapy are not ad-dressed. See Table 5 for definitions of disease activity and features of poor prognosis. MTX �methotrexate; TNF� � tumor necrosis factor �; * � initiation of anakinra for the treatmentof arthritis may be less appropriate later in the disease course compared to nearer the onsetof disease; † � switching from anakinra to a TNF� inhibitor may be appropriate for somepatients with moderate or high disease activity, irrespective of features of poor prognosis,but there is a possible risk of unmasking latent systemic features when discontinuinganakinra.


received methotrexate and a TNF� inhibitor or methotrex-ate and abatacept and have high or moderate disease ac-tivity, irrespective of poor prognostic factors (level C)(16,101–103). Although not formally assessed using theRAND/UCLA Appropriateness Method, there was consen-sus among the TFP that initiation of anakinra for the treat-ment of arthritis may be less appropriate later in the dis-ease course compared to nearer to the onset of disease.

TNF� inhibitor. Initiation (addition) of a TNF� inhibi-tor was recommended for patients who have received 3months of methotrexate and have moderate or high diseaseactivity, irrespective of features of poor prognosis (level B)(10,15). The TFP expressed that it may be appropriate toswitch therapy from anakinra to a TNF� inhibitor for pa-tients with moderate or high disease activity, irrespectiveof features of poor prognosis (level D). However, concernwas expressed regarding possible unmasking of latent sys-temic disease activity when discontinuing anakinra.

Abatacept. Initiation of abatacept was recommendedfor patients who have received methotrexate and a TNF�

inhibitor and have high disease activity, irrespective offeatures of poor prognosis, or have moderate disease activ-ity and poor prognostic features (level B) (17).

Calcineurin inhibitors. Initiation of calcineurin inhibi-tors was inappropriate for patients with active arthritisand without active systemic features (level C) (105,106).

Safety monitoring. The TFP evaluated the appropriate-ness of several safety monitoring interventions by consid-ering the health benefits (minimizing the chance of toxic-ity or adverse events) and harms (frequent phlebotomies,false-positive test results). As with the evaluation of initi-ation of therapeutic agents, the TFP did not consider theeconomic costs of monitoring or adverse events. A sum-mary of the recommendations for medication safety mon-itoring is shown in Table 6.

NSAID monitoring. Measurement of serum creatinine,urinalysis, complete blood count, and liver enzymes wasrecommended prior to or soon after the initiation of treat-ment with routine NSAIDs (level D). Periodic repeat mea-surements of serum creatinine, urinalysis, complete bloodcount, and liver enzymes were recommended approxi-mately twice yearly for patients receiving long-term dailyNSAIDs and approximately once yearly for patients receiv-ing NSAIDs routinely (e.g., 3 to 4 days per week) (level D).

Methotrexate monitoring. Measurement of serum creat-inine, complete blood count, and liver enzymes was rec-ommended prior to initiation of methotrexate (level D).Shortly after initiation of methotrexate, repeat measure-ments of serum creatinine, complete blood count, andliver enzymes were recommended. No single preferredmonitoring strategy was recommended. In general, theTFP recommended laboratory measurements approxi-mately 1 month after initiating methotrexate and thenapproximately 1 to 2 months after any subsequent increasein methotrexate dose (level D). Repeat measurements ofserum creatinine, complete blood count, and liver en-zymes were recommended approximately every 3 to 4months for patients receiving a stable dose of methotrexatewith no recent history of abnormal laboratory monitoring

results (level C) (107,108). Although not formally evalu-ated using the RAND/UCLA Appropriateness Method,there was consensus among the TFP that laboratory mea-surements be obtained 1 to 2 days prior to the scheduledweekly dose of methotrexate.

The TFP made several recommendations about appro-priate responses to elevated liver enzymes for patientsreceiving methotrexate. In response to liver enzyme eleva-tion of as much as 2 times the upper limit of normal, eitherno specific action or rechecking liver enzymes at a shorterinterval was recommended. In response to liver enzymeelevation more than 2 times the upper limit of normal,decreasing the dose of methotrexate or temporarily with-holding methotrexate administration was recommended.If liver enzymes remain at levels more than 3 times theupper limit of normal following a decrease in the metho-trexate dose, discontinuation of methotrexate was recom-mended (all recommendations are level C) (107–110).

TNF� inhibitor monitoring. Measurement of completeblood count, liver enzymes, and serum creatinine wasrecommended prior to initiation of TNF� inhibitors andapproximately every 3 to 6 months thereafter for patientswho continue to receive TNF� inhibitors (level D).

Tuberculosis screening. Obtaining Mantoux purifiedprotein derivative skin testing for tuberculosis was recom-mended prior to initiation of TNF� inhibitors for all pa-tients (level C) (111). Repeat testing approximately onceyearly thereafter was recommended for all patients whocontinue to receive TNF� inhibitors (level D). The appro-priateness of interferon-� release assays for detecting tu-berculosis was not evaluated. The appropriateness of tu-berculosis testing prior to the initiation of biologic agentsother than TNF� inhibitors was not evaluated.

Hepatitis B and hepatitis C screening. Antibody testingfor infection with hepatitis B or hepatitis C prior to initi-

Table 6. Summary of recommendations for medicationsafety monitoring

NONSTEROIDAL ANTIINFLAMMATORY DRUGSComplete blood count, liver enzymes, serum creatinine

Prior to or soon after initiation of routine useRepeat approximately twice yearly for chronic daily

useRepeat approximately once yearly for routine use

(3–4 days per week)

METHOTREXATEComplete blood count, liver enzymes, serum creatinine

Prior to initiationApproximately 1 month after initiationApproximately 1–2 months after increase in doseRepeat approximately every 3–4 months if prior

results normal and dose stable

TUMOR NECROSIS FACTOR � INHIBITORSComplete blood count, liver enzymes, serum creatinine

Prior to initiationRepeat approximately every 3–6 months

Tuberculosis screeningPrior to initiationRepeat approximately once yearly

478 Beukelman et al

ating methotrexate or TNF� inhibitors was recommendedfor patients with risk factors for infection (level D). Riskfactors for hepatitis B and hepatitis C infections are shownin Supplementary Appendix C (available in the onlineversion of this article at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2151-4658).

DISCUSSION

Following a systematic review of the literature and using aformal group assessment process, we provide evidenceand consensus-based recommendations for the appropri-ate initiation and safety monitoring of therapeutic agentsin the treatment of JIA. These recommendations are meantas a guide to health care providers caring for children withJIA and are not meant to take the place of individualizedcare or to serve as health care coverage guidelines. Theserecommendations will require future updates as scientificknowledge expands regarding the benefits and risks of thetreatment of JIA.

Addendum. Therapies that were approved after the originalliterature review are not included in these recommendations.

ACKNOWLEDGMENTWe thank Ms Amy Miller and Ms Regina Parker of the ACRfor administrative support and guidance.

AUTHOR CONTRIBUTIONS

All authors were involved in drafting the article or revising itcritically for important intellectual content, and all authors ap-proved the final version to be published. Dr. Beukelman had fullaccess to all of the data in the study and takes responsibility forthe integrity of the data and the accuracy of the data analysis.Study conception and design. Beukelman, Patkar, Saag, Tolleson-Rinehart, Cron, DeWitt, Ilowite, Kimura, Laxer, Lovell, Martini,Rabinovich, Ruperto.Acquisition of data. Beukelman, Patkar, Saag, Tolleson-Rinehart,Cron, DeWitt, Ilowite, Kimura, Laxer, Lovell, Martini, Rabinovich,Ruperto.Analysis and interpretation of data. Beukelman, Patkar, Saag,Tolleson-Rinehart, Cron, DeWitt, Ilowite, Kimura, Laxer, Lovell,Martini, Rabinovich, Ruperto.

REFERENCES

1. Petty RE, Southwood TR, Manners P, Baum J, Glass DN,Goldenberg J, et al. International League of Associations forRheumatology classification of juvenile idiopathic arthritis:second revision, Edmonton, 2001. J Rheumatol 2004;31:390–2.

2. Andersson Gare B. Juvenile arthritis: who gets it, where andwhen? A review of current data on incidence and preva-lence. Clin Exp Rheumatol 1999;17:367–74.

3. Hanova P, Pavelka K, Dostal C, Holcatova I, Pikhart H. Epi-demiology of rheumatoid arthritis, juvenile idiopathic arthri-tis and gout in two regions of the Czech Republic in adescriptive population-based survey in 2002-2003. Clin ExpRheumatol 2006;24:499–507.

4. Selvaag AM, Flato B, Dale K, Lien G, Vinje O, Smerdel-Ramoya A, et al. Radiographic and clinical outcome in earlyjuvenile rheumatoid arthritis and juvenile spondylo-arthropathy: a 3-year prospective study. J Rheumatol 2006;33:1382–91.

5. Van Rossum MA, Zwinderman AH, Boers M, Dijkmans BA,van Soesbergen RM, Fiselier TJ, et al, for the Dutch JuvenileIdiopathic Arthritis Study Group. Radiologic features in ju-

venile idiopathic arthritis: a first step in the development ofa standardized assessment method. Arthritis Rheum 2003;48:507–15.

6. Zak M, Pedersen FK. Juvenile chronic arthritis intoadulthood: a long-term follow-up study. Rheumatology (Ox-ford) 2000;39:198–204.

7. Minden K, Niewerth M, Listing J, Biedermann T, Bollow M,Schontube M, et al. Long-term outcome in patients withjuvenile idiopathic arthritis. Arthritis Rheum 2002;46:2392–401.

8. Bowyer SL, Roettcher PA, Higgins GC, Adams B, Myers LK,Wallace C, et al. Health status of patients with juvenilerheumatoid arthritis at 1 and 5 years after diagnosis. J Rheu-matol 2003;30:394–400.

9. Packham JC, Hall MA. Long-term follow-up of 246 adultswith juvenile idiopathic arthritis: functional outcome. Rheu-matology (Oxford) 2002;41:1428–35.

10. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, SilvermanED, Nocton JJ, et al, for the Pediatric Rheumatology Collab-orative Study Group. Etanercept in children with polyartic-ular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763–9.

11. Henrickson M, Reiff A. Prolonged efficacy of etanercept inrefractory enthesitis-related arthritis. J Rheumatol 2004;31:2055–61.

12. Horneff G, Schmeling H, Biedermann T, Foeldvari I, GanserG, Girschick HJ, et al. The German etanercept registry fortreatment of juvenile idiopathic arthritis. Ann Rheum Dis2004;63:1638–44.

13. Gerloni V, Pontikaki I, Gattinara M, Desiati F, Lupi E, LuratiA, et al. Efficacy of repeated intravenous infusions of ananti–tumor necrosis factor � monoclonal antibody, inflix-imab, in persistently active, refractory juvenile idiopathicarthritis: results of an open-label prospective study. ArthritisRheum 2005;52:548–53.

14. Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL,et al, for the Pediatric Rheumatology Collaborative StudyGroup. Safety and efficacy of up to eight years of continuousetanercept therapy in patients with juvenile rheumatoid ar-thritis. Arthritis Rheum 2008;58:1496–504.

15. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, JarosovaK, et al. Adalimumab with or without methotrexate in juve-nile rheumatoid arthritis. N Engl J Med 2008;359:810–20.

16. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Roleof interleukin-1 (IL-1) in the pathogenesis of systemic onsetjuvenile idiopathic arthritis and clinical response to IL-1blockade. J Exp Med 2005;201:1479–86.

17. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, SilvaCA, et al. Abatacept in children with juvenile idiopathicarthritis: a randomised, double-blind, placebo-controlledwithdrawal trial. Lancet 2008;372:383–91.

18. Fitch K, Bernstein SJ, Aguilar MD, Burnand B, Lacalle JR,Lazaro P. The RAND/UCLA Appropriateness Method user’smanual. Pittsburgh: RAND; 2000.

19. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, CurtisJR, et al. American College of Rheumatology 2008 recom-mendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Ar-thritis Rheum 2008;59:762–84.

20. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L,Chen W, et al. American College of Rheumatology 2010recommendations for the prevention and treatment of gluco-corticoid-induced osteoporosis. Arthritis Care Res (Hobo-ken) 2010;62:1515–26.

21. The AGREE Collaboration. Appraisal of Guidelines for Re-search and Education (AGREE) instrument. St. George’s Hos-pital Medical School. 2001. URL: www.agreecollabora-tion.org.

22. Cassidy JT, Petty RE. Systemic arthritis. In: Cassidy JT, PettyRE, Laxer RM, Lindsley CB, editors. Textbook of pediatricrheumatology. 5th ed. Philadelphia: WB Saunders; 2005. p.291–303.

23. Flato B, Lien G, Smerdel A, Vinje O, Dale K, Johnston V, etal. Prognostic factors in juvenile rheumatoid arthritis: a case-


control study revealing early predictors and outcome after14.9 years. J Rheumatol 2003;30:386–93.

24. Flato B, Smerdel A, Johnston V, Lien G, Dale K, Vinje O, etal. The influence of patient characteristics, disease variables,and HLA alleles on the development of radiographicallyevident sacroiliitis in juvenile idiopathic arthritis. ArthritisRheum 2002;46:986–94.

25. Flato B, Hoffmann-Vold AM, Reiff A, Forre O, Lien G, VinjeO. Long-term outcome and prognostic factors in enthesitis-related arthritis: a case–control study. Arthritis Rheum 2006;54:3573–82.

26. Al-Matar MJ, Petty RE, Tucker LB, Malleson PN, SchroederML, Cabral DA. The early pattern of joint involvement pre-dicts disease progression in children with oligoarticular(pauciarticular) juvenile rheumatoid arthritis. ArthritisRheum 2002;46:2708–15.

27. Gare BA, Fasth A. The natural history of juvenile chronicarthritis: a population based cohort study. I. Onset and dis-ease process. J Rheumatol 1995;22:295–307.

28. Ruperto N, Ravelli A, Levinson JE, Shear ES, Murray K, LinkTague B, et al. Long-term health outcomes and quality of lifein American and Italian inception cohorts of patients withjuvenile rheumatoid arthritis. II. Early predictors of out-come. J Rheumatol 1997;24:952–8.

29. Guillaume S, Prieur AM, Coste J, Job-Deslandre C. Long-termoutcome and prognosis in oligoarticular-onset juvenile idio-pathic arthritis. Arthritis Rheum 2000;43:1858–65.

30. Flato B, Aasland A, Vinje O, Forre O. Outcome and predic-tive factors in juvenile rheumatoid arthritis and juvenilespondyloarthropathy. J Rheumatol 1998;25:366–75.

31. Magni-Manzoni S, Rossi F, Pistorio A, Temporini F, Viola S,Beluffi G, et al. Prognostic factors for radiographic progres-sion, radiographic damage, and disability in juvenile idio-pathic arthritis. Arthritis Rheum 2003;48:3509–17.

32. Gare BA, Fasth A. The natural history of juvenile chronicarthritis: a population based cohort study. II. Outcome.J Rheumatol 1995;22:308–19.

33. Gilliam BE, Chauhan AK, Low JM, Moore TL. Measurementof biomarkers in juvenile idiopathic arthritis patients andtheir significant association with disease severity: a compar-ative study. Clin Exp Rheumatol 2008;26:492–7.

34. Habib HM, Mosaad YM, Youssef HM. Anti-cyclic citrulli-nated peptide antibodies in patients with juvenile idiopathicarthritis. Immunol Invest 2008;37:849–57.

35. Schneider R, Lang BA, Reilly BJ, Laxer RM, Silverman ED,Ibanez D, et al. Prognostic indicators of joint destruction insystemic-onset juvenile rheumatoid arthritis. J Pediatr 1992;120:200–5.

36. Spiegel LR, Schneider R, Lang BA, Birdi N, Silverman ED,Laxer RM, et al. Early predictors of poor functional outcomein systemic-onset juvenile rheumatoid arthritis: a multi-center cohort study. Arthritis Rheum 2000;43:2402–9.

37. Singh-Grewal D, Schneider R, Bayer N, Feldman BM. Pre-dictors of disease course and remission in systemic juvenileidiopathic arthritis: significance of early clinical and labora-tory features. Arthritis Rheum 2006;54:1595–601.

38. Modesto C, Woo P, Garcia-Consuegra J, Merino R, Garcia-Granero M, Arnal C, et al. Systemic onset juvenile chronicarthritis, polyarticular pattern and hip involvement as mark-ers for a bad prognosis. Clin Exp Rheumatol 2001;19:211–7.

39. Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Man-zoni S, Filocamo G, et al, for the Paediatric RheumatologyInternational Trials Organisation. Development and valida-tion of a composite disease activity score for juvenile idio-pathic arthritis. Arthritis Rheum 2009;61:658–66.

40. Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de OliveiraSK, Falcini F, et al, for the Pediatric Rheumatology Interna-tional Trials Organization. A randomized trial of parenteralmethotrexate comparing an intermediate dose with a higherdose in children with juvenile idiopathic arthritis who failedto respond to standard doses of methotrexate. ArthritisRheum 2004;50:2191–201.

41. Ruperto N, Nikishina I, Pachanov ED, Shachbazian Y, PrieurAM, Mouy R, et al, for the Pediatric Rheumatology Interna-tional Trials Organization. A randomized, double-blind clin-

ical trial of two doses of meloxicam compared withnaproxen in children with juvenile idiopathic arthritis:short- and long-term efficacy and safety results. ArthritisRheum 2005;52:563–72.

42. Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, EspadaG, et al, for the Paediatric Rheumatology International TrialsOrganisation and the Pediatric Rheumatology CollaborativeStudy Group. A randomized, placebo-controlled trial of in-fliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007;56:3096–106.

43. Magni-Manzoni S, Ruperto N, Pistorio A, Sala E, Solari N,Palmisani E, et al. Development and validation of a prelim-inary definition of minimal disease activity in patients withjuvenile idiopathic arthritis. Arthritis Rheum 2008;59:1120–7.

44. Genovese MC, Cohen S, Moreland L, Lium D, Robbins S,Newmark R, et al, for the 20000223 Study Group. Combina-tion therapy with etanercept and anakinra in the treatment ofpatients with rheumatoid arthritis who have been treatedunsuccessfully with methotrexate. Arthritis Rheum 2004;50:1412–9.

45. Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC,Keystone E. Safety of the selective costimulation modulatorabatacept in rheumatoid arthritis patients receiving back-ground biologic and nonbiologic disease-modifying anti-rheumatic drugs: a one-year randomized, placebo-controlledstudy. Arthritis Rheum 2006;54:2807–16.

46. Oxford Centre for Evidence Based Medicine. Levels of evi-dence. 2009. URL: http://www.cebm.net/index.aspx?o�1025.

47. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P,Gaujoux-Viala C, et al. EULAR recommendations for themanagement of rheumatoid arthritis with synthetic and bio-logical disease-modifying antirheumatic drugs. Ann RheumDis 2010;69:964–75.

48. Sherry DD, Stein LD, Reed AM, Schanberg LE, Kredich DW.Prevention of leg length discrepancy in young children withpauciarticular juvenile rheumatoid arthritis by treatmentwith intraarticular steroids. Arthritis Rheum 1999;42:2330–4.

49. Marti P, Molinari L, Bolt IB, Seger R, Saurenmann RK. Fac-tors influencing the efficacy of intra-articular steroid injec-tions in patients with juvenile idiopathic arthritis. Eur J Pe-diatr 2008;167:425–30.

50. Beukelman T, Arabshahi B, Cahill AM, Kaye RD, Cron RQ.Benefit of intraarticular corticosteroid injection under fluo-roscopic guidance for subtalar arthritis in juvenile idiopathicarthritis. J Rheumatol 2006;33:2330–6.

51. Eberhard BA, Sison MC, Gottlieb BS, Ilowite NT. Compari-son of the intraarticular effectiveness of triamcinolonehexacetonide and triamcinolone acetonide in treatment ofjuvenile rheumatoid arthritis. J Rheumatol 2004;31:2507–12.

52. Zulian F, Martini G, Gobber D, Plebani M, Zacchello F,Manners P. Triamcinolone acetonide and hexacetonide in-tra-articular treatment of symmetrical joints in juvenile id-iopathic arthritis: a double-blind trial. Rheumatology (Ox-ford) 2004;43:1288–91.

53. Zulian F, Martini G, Gobber D, Agosto C, Gigante C, Zac-chello F. Comparison of intra-articular triamcinolonehexacetonide and triamcinolone acetonide in oligoarticularjuvenile idiopathic arthritis. Rheumatology (Oxford) 2003;42:1254–9.

54. Lepore L, del Santo M, Malorgio C, Presani G, Perticarari S,Prodan M, et al. Treatment of juvenile idiopathic arthritiswith intra-articular triamcinolone hexacetonide: evaluationof clinical effectiveness correlated with circulating ANA andT �/� � and B CD5� lymphocyte populations of synovialfluid. Clin Exp Rheumatol 2002;20:719–22.

55. Neidel J, Boehnke M, Kuster RM. The efficacy and safety ofintraarticular corticosteroid therapy for coxitis in juvenilerheumatoid arthritis. Arthritis Rheum 2002;46:1620–8.

56. Ravelli A, Manzoni SM, Viola S, Pistorio A, Ruperto N,Martini A. Factors affecting the efficacy of intraarticular

480 Beukelman et al

corticosteroid injection of knees in juvenile idiopathic ar-thritis. J Rheumatol 2001;28:2100–2.

57. Breit W, Frosch M, Meyer U, Heinecke A, Ganser G. Asubgroup-specific evaluation of the efficacy of intraarticulartriamcinolone hexacetonide in juvenile chronic arthritis.J Rheumatol 2000;27:2696–702.

58. Yang MH, Lee WI, Chen LC, Lin SJ, Huang JL. Intraarticulartriamcinolone hexacetonide injection in children withchronic arthritis: a survey of clinical practice. Acta PaediatrTaiwan 1999;40:182–5.

59. Padeh S, Passwell JH. Intraarticular corticosteroid injectionin the management of children with chronic arthritis. Arthri-tis Rheum 1998;41:1210–4.

60. Remedios D, Martin K, Kaplan G, Mitchell R, Woo P, RooneyM. Juvenile chronic arthritis: diagnosis and management oftibio-talar and sub-talar disease. Br J Rheumatol 1997;36:1214–7.

61. Eich GF, Halle F, Hodler J, Seger R, Willi UV. Juvenilechronic arthritis: imaging of the knees and hips before andafter intraarticular steroid injection. Pediatr Radiol 1994;24:558–63.

62. Honkanen VE, Rautonen JK, Pelkonen PM. Intra-articularglucocorticoids in early juvenile chronic arthritis. Acta Pae-diatr 1993;82:1072–4.

63. Hertzberger-ten Cate R, de Vries-van der Vlugt BC, van Sui-jlekom-Smit LW, Cats A. Intra-articular steroids in pau-ciarticular juvenile chronic arthritis, type 1. Eur J Pediatr1991;150:170–2.

64. Earley A, Cuttica RJ, McCullough C, Ansell BM. Triamcino-lone into the knee joint in juvenile chronic arthritis. Clin ExpRheumatol 1988;6:153–5.

65. Allen RC, Gross KR, Laxer RM, Malleson PN, BeauchampRD, Petty RE. Intraarticular triamcinolone hexacetonide inthe management of chronic arthritis in children. ArthritisRheum 1986;29:997–1001.

66. Beukelman T, Guevara JP, Albert DA. Optimal treatment ofknee monarthritis in juvenile idiopathic arthritis: a decisionanalysis. Arthritis Rheum 2008;59:1580–8.

67. Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H,Moebius D, et al. Safety and efficacy of combination of etan-ercept and methotrexate compared to treatment with etaner-cept only in patients with juvenile idiopathic arthritis (JIA):preliminary data from the German JIA Registry. Ann RheumDis 2009;68:519–25.

68. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D,Macfarlane JD, et al. Therapeutic efficacy of multiple intra-venous infusions of anti–tumor necrosis factor � monoclonalantibody combined with low-dose weekly methotrexate inrheumatoid arthritis. Arthritis Rheum 1998;41:1552–63.

69. Infliximab [package insert]. Malvern (PA): Centocor OrthoBiotech; 2010.

70. Giannini EH, Brewer EJ, Miller ML, Gibbas D, Passo MH,Hoyeraal HM, et al, for the Pediatric Rheumatology Collab-orative Study Group. Ibuprofen suspension in the treatmentof juvenile rheumatoid arthritis. J Pediatr 1990;117:645–52.

71. Bhettay E. Double-blind study of sulindac and aspirin injuvenile chronic arthritis. S Afr Med J 1986;70:724–6.

72. Kvien TK, Hoyeraal HM, Sandstad B. Naproxen and acetyl-salicylic acid in the treatment of pauciarticular and polyar-ticular juvenile rheumatoid arthritis: assessment of toleranceand efficacy in a single-centre 24-week double-blind parallelstudy. Scand J Rheumatol 1984;13:342–50.

73. Haapasaari J, Wuolijoki E, Ylijoki H. Treatment of juvenilerheumatoid arthritis with diclofenac sodium. Scand J Rheu-matol 1983;12:325–30.

74. Brewer EJ, Giannini EH, Baum J, Bernstein B, Fink CW,Emery HM, et al. Aspirin and fenoprofen (Nalfon) in thetreatment of juvenile rheumatoid arthritis results of the dou-ble blind-trial: a segment II study. J Rheumatol 1982;9:123–8.

75. Moran H, Hanna DB, Ansell BM, Hall M, Engler C. Naproxenin juvenile chronic polyarthritis. Ann Rheum Dis 1979;38:152–4.

76. Levinson JE, Baum J, Brewer E Jr, Fink C, Hanson V, SchallerJ. Comparison of tolmetin sodium and aspirin in the treat-

ment of juvenile rheumatoid arthritis. J Pediatr 1977;91:799–804.

77. Silverman E, Mouy R, Spiegel L, Jung LK, Saurenmann RK,Lahdenne P, et al. Leflunomide or methotrexate for juvenilerheumatoid arthritis. N Engl J Med 2005;352:1655–66.

78. Woo P, Southwood TR, Prieur AM, Dore CJ, Grainger J,David J, et al. Randomized, placebo-controlled, crossovertrial of low-dose oral methotrexate in children with ex-tended oligoarticular or systemic arthritis. Arthritis Rheum2000;43:1849–57.

79. Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A,Vorontsov I, et al, for the Pediatric Rheumatology Collabor-ative Study Group and the Cooperative Children’s StudyGroup. Methotrexate in resistant juvenile rheumatoidarthritis: results of the USA-USSR double-blind, placebo-controlled trial. N Engl J Med 1992;326:1043–9.

80. Albers HM, Wessels JA, van der Straaten RJ, Brinkman DM,Suijlekom-Smit LW, Kamphuis SS, et al. Time to treatmentas an important factor for the response to methotrexate injuvenile idiopathic arthritis. Arthritis Rheum 2009;61:46–51.

81. Brik R, Gepstein V, Berkovitz D. Low-dose methotrexatetreatment for oligoarticular juvenile idiopathic arthritis non-responsive to intra-articular corticosteroids. Clin Rheumatol2005;24:612–4.

82. Alsufyani K, Ortiz-Alvarez O, Cabral DA, Tucker LB, PettyRE, Malleson PN. The role of subcutaneous administration ofmethotrexate in children with juvenile idiopathic arthritiswho have failed oral methotrexate. J Rheumatol 2004;31:179–82.

83. Lin YT, Tsai MJ, Wang LH, Huang MT, Yang YH, Chiang BL.Efficacy and safety of methotrexate therapy for juvenile rheu-matoid arthritis. J Formos Med Assoc 2000;99:623–9.

84. Van Rossum MA, Fiselier TJ, Franssen MJ, Zwinderman AH,ten Cate R, van Suijlekom-Smit LW, et al, for the DutchJuvenile Chronic Arthritis Study Group. Sulfasalazine in thetreatment of juvenile chronic arthritis: a randomized, dou-ble-blind, placebo-controlled, multicenter study. ArthritisRheum 1998;41:808–16.

85. Tse SM, Burgos-Vargas R, Laxer RM. Anti–tumor necrosisfactor � blockade in the treatment of juvenile spondylar-thropathy. Arthritis Rheum 2005;52:2103–8.

86. Brewer EJ, Giannini EH, Kuzmina N, Alekseev L. Penicilla-mine and hydroxychloroquine in the treatment of severejuvenile rheumatoid arthritis: results of the USA-USSR dou-ble-blind placebo-controlled trial. N Engl J Med 1986;314:1269–76.

87. Van Rossum MA, van Soesbergen RM, Boers M, Zwinder-man AH, Fiselier TJ, Franssen MJ, et al. Long-term outcomeof juvenile idiopathic arthritis following a placebo-con-trolled trial: sustained benefits of early sulfasalazine treat-ment. Ann Rheum Dis 2007;66:1518–24.

88. Prince FH, Twilt M, ten Cate R, van Rossum MA, ArmbrustW, Hoppenreijs EP, et al. Long-term follow-up on effective-ness and safety of etanercept in juvenile idiopathic arthritis:the Dutch National Register. Ann Rheum Dis 2009;68:635–41.

89. Tynjala P, Vahasalo P, Honkanen V, Lahdenne P. Drug sur-vival of the first and second course of anti-tumour necrosisfactor agents in juvenile idiopathic arthritis. Ann Rheum Dis2009;68:552–7.

90. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA,Genovese MC, et al, for the REFLEX Trial Group. Rituximabfor rheumatoid arthritis refractory to anti–tumor necrosisfactor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primaryefficacy and safety at twenty-four weeks. Arthritis Rheum2006;54:2793–806.

91. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schech-tman J, Szczepanski L, Kavanaugh A, et al, for the DANCERStudy Group. The efficacy and safety of rituximab in patientswith active rheumatoid arthritis despite methotrexatetreatment: results of a phase IIb randomized, double-blind,placebo-controlled, dose-ranging trial. Arthritis Rheum2006;54:1390–400.


92. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sos-nowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoidarthritis. N Engl J Med 2004;350:2572–81.

93. Schmeling H, Horneff G. Infliximab in two patients withjuvenile ankylosing spondylitis. Rheumatol Int 2004;24:173–6.

94. McLeod C, Bagust A, Boland A, Dagenais P, Dickson R,Dundar Y, et al. Adalimumab, etanercept and infliximab forthe treatment of ankylosing spondylitis: a systematic reviewand economic evaluation. Health Technol Assess 2007;11:1–158, iii–iv.

95. Katsicas MM, Russo RA. Use of infliximab in patients withsystemic juvenile idiopathic arthritis refractory to etaner-cept. Clin Exp Rheumatol 2005;23:545–8.

96. Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, BostM, et al. Efficacy of etanercept for the treatment of juvenileidiopathic arthritis according to the onset type. ArthritisRheum 2003;48:1093–101.

97. Russo RA, Katsicas MM. Clinical remission in patients withsystemic juvenile idiopathic arthritis treated with anti-tumornecrosis factor agents. J Rheumatol 2009;36:1078–82.

98. Kimura Y, Pinho P, Walco G, Higgins G, Hummell D, Szer I,et al. Etanercept treatment in patients with refractory sys-temic onset juvenile rheumatoid arthritis. J Rheumatol 2005;32:935–42.

99. Pay S, Turkcapar N, Kalyoncu M, Simsek I, Beyan E, ErtenliI, et al. A multicenter study of patients with adult-onsetStill’s disease compared with systemic juvenile idiopathicarthritis. Clin Rheumatol 2006;25:639–44.

100. Picco P, Gattorno M, Buoncompagni A, Pistoia V, Borrone C.6-methylprednisolone ‘mini-pulses’: a new modality of glu-cocorticoid treatment in systemic onset juvenile chronic ar-thritis. Scand J Rheumatol 1996;25:24–7.

101. Gattorno M, Piccini A, Lasiglie D, Tassi S, Brisca G, Carta S,et al. The pattern of response to anti–interleukin-1 treatmentdistinguishes two subsets of patients with systemic-onsetjuvenile idiopathic arthritis. Arthritis Rheum 2008;58:1505–15.

102. Verbsky JW, White AJ. Effective use of the recombinantinterleukin 1 receptor antagonist anakinra in therapy resis-

tant systemic onset juvenile rheumatoid arthritis. J Rheuma-tol 2004;31:2071–5.

103. Zeft A, Hollister R, LaFleur B, Sampath P, Soep J, McNally B,et al. Anakinra for systemic juvenile arthritis: the RockyMountain experience. J Clin Rheumatol 2009;15:161–4.

104. Ilowite N, Porras O, Reiff A, Rudge S, Punaro M, Martin A, etal. Anakinra in the treatment of polyarticular-course juve-nile rheumatoid arthritis: safety and preliminary efficacyresults of a randomized multicenter study. Clin Rheumatol2009;28:129–37.

105. Ruperto N, Ravelli A, Castell E, Gerloni V, Haefner R, Malat-tia C, et al. Cyclosporine A in juvenile idiopathic arthritis:results of the PRCSG/PRINTO phase IV post marketing sur-veillance study. Clin Exp Rheumatol 2006;24:599–605.

106. Gerloni V, Cimaz R, Gattinara M, Arnoldi C, Pontikaki I,Fantini F. Efficacy and safety profile of cyclosporin A in thetreatment of juvenile chronic (idiopathic) arthritis: results ofa 10-year prospective study. Rheumatology (Oxford) 2001;40:907–13.

107. Ortiz-Alvarez O, Morishita K, Avery G, Green J, Petty RE,Tucker LB, et al. Guidelines for blood test monitoring ofmethotrexate toxicity in juvenile idiopathic arthritis. J Rheu-matol 2004;31:2501–6.

108. Kocharla L, Taylor J, Weiler T, Ting TV, Luggen M, BrunnerHI. Monitoring methotrexate toxicity in juvenile idiopathicarthritis. J Rheumatol 2009;36:2813–8.

109. Lahdenne P, Rapola J, Ylijoki H, Haapasaari J. Hepatotoxic-ity in patients with juvenile idiopathic arthritis receivinglong-term methotrexate therapy. J Rheumatol 2002;29:2442–5.

110. Wallace CA, Bleyer WA, Sherry DD, Salmonson KL, Wedg-wood RJ. Toxicity and serum levels of methotrexate in chil-dren with juvenile rheumatoid arthritis. Arthritis Rheum1989;32:677–81.

111. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, MonteroD, Pascual-Gomez E, Mola EM, et al, for the BIOBADASERGroup. Effectiveness of recommendations to prevent reacti-vation of latent tuberculosis infection in patients treatedwith tumor necrosis factor antagonists. Arthritis Rheum2005;52:1766–72.

482 Beukelman et al

2011 american college of rheumatology recommendations …the american college of rheumatology is an...

Documents